In the last trading session, 1.91 million AN2 Therapeutics Inc (NASDAQ:ANTX) shares changed hands as the company’s beta touched -0.08. With the company’s per share price at $0.98 changed hands at -$0.04 or -3.92% during last session, the market valuation stood at $29.24M. ANTX’s last price was a discount, traded about -2167.35% off its 52-week high of $22.22. The share price had its 52-week low at $0.87, which suggests the last value was 11.22% up since then. When we look at AN2 Therapeutics Inc’s average trading volume, we note the 10-day average is 2.16 million shares, with the 3-month average coming to 452.26K.

Analysts gave the AN2 Therapeutics Inc (ANTX) stock a consensus recommendation rating of Buy, calculated at a mean rating of 2.60. If we narrow down to specifics, the data shows that 0 out of 3 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 0 recommended ANTX as a Hold, 3 felt it is a Buy and 0 rated the stock as Underweight. AN2 Therapeutics Inc’s EPS for the current quarter is expected to be -0.48.

AN2 Therapeutics Inc (NASDAQ:ANTX) trade information

Instantly ANTX was in red as seen at the end of in last trading. With action -4.85%, the performance over the past five days has been red. The company’s shares are showing year-to-date downside of -95.22%, with the 5-day performance at -4.85% in the red. However, in the 30-day time frame, AN2 Therapeutics Inc (NASDAQ:ANTX) is -65.61% down. Looking at the short shares, we see there were 0.68 million shares sold at short interest cover period of 3.47 days.

The consensus price target for the stock as assigned by Wall Street analysts is 5.5, meaning bulls need an upside of 82.18% from its current market value. According to analyst projections, ANTX’s forecast low is 2 with 22 as the target high. To hit the forecast high, the stock’s price needs a -2144.9% plunge from its current level, while the stock would need to soar -104.08% for it to hit the projected low.

AN2 Therapeutics Inc (ANTX) estimates and forecasts

Data shows that the AN2 Therapeutics Inc share is performing relatively much better than most of its peers within the same industry. As can be gleaned from the statistics, the company’s share value shot -74.55% over the past 6 months, a 29.20% in annual growth rate that is considerably higher than the industry average of 18.00%.

Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of -73.03%. The 2024 estimates are for AN2 Therapeutics Inc earnings to increase by 25.99%.

ANTX Dividends

AN2 Therapeutics Inc is expected to release its next quarterly earnings report 2024-Aug-13.

AN2 Therapeutics Inc (NASDAQ:ANTX)’s Major holders

If we look at who the major shareholders are, we find that insiders hold 25.37% of AN2 Therapeutics Inc shares while 84.10% of the shares are in the hands of institutional holders. The share float percentage for the stock currently stands at 112.70%. There are 84.10% institutions holding the AN2 Therapeutics Inc stock share, with RA CAPITAL MANAGEMENT, L.P. the top institutional holder. As of 2024-03-31, the company held 23.5223% of the shares, roughly 5.55 million ANTX shares worth $18.04 million.

CITADEL ADVISORS LLC holds the second largest percentage of outstanding shares, with 6.5955% or 1.56 million shares worth $5.06 million as of 2024-03-31.

Among Mutual Funds, the top two as of Mar 31, 2024 were Vanguard Total Stock Market Index Fund and Vanguard Extended Market Index Fund . With 749.42 shares estimated at $0.73 million under it, the former controlled 2.51% of total outstanding shares. On the other hand, Vanguard Extended Market Index Fund held about 0.88% of the shares, roughly 261.93 shares worth around $0.26 million.